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R. conorii) (9,10). Higher reciprocal
titers were obtained against R. akari
antigens than against R. rickettsii and
R. conorii antigens (reciprocol titers
of 1,024 vs. 512 and 512,
respectively). We observed a
difference in reduction in antibody
titers against R. akari after adsorption
with  R. akari (Kaplan) (<16), R.
rickettsii (256), and R. conorii (256).
Antibodies against R. typhi were not
detected. The IFAresult confirmed the
clinical diagnosis of R. akari
infection. After 2 days of doxycycline
treatment, the patient was afebrile,
and the rickettsialpox infection
resolved without scars or
complications.
In summary, we present a case in
which the presence of an eschar on the
patient’s penis, the failure of lesions
to appear in crops, the sparsity of
lesions, and mice on the family’s farm
led to a diagnosis of rickettsialpox,
which was confirmed by cross-
adsorption serologic findings. This
case indicates that rickettsialpox is an
emerging infectious disease in
Turkey. We recommend further
studies to define the prevalence of R.
akari and the worldwide distribution
of rickettsialpox.
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To the Editor: We report a case of
a 24-year-old woman living in a rural
area of Estonia who had weakness,
chills, and diarrhea on May 10, 2002.
On day 5 of the illness, she was
admitted to the Department of
Infectious Diseases, University of
Tartu, with high fever (38.5°C) and
muscle pains throughout her body.
Examination showed mild jaundice,
painful and enlarged liver, and inabil-
ity to move. Throat was erythematous,
and enlarged lymph nodes were pal-
pable on the neck.
Laboratory findings included the
following: leukopenia 2.04x109/L;
erythrocytes 4.08x1012/L; hemoglobin
130 g/L; thrombocytopenia 36x109/L;
eosinophils 0%; basophils 1.0%;
monocytes 7.5%; lymphocytes 38.0%;
neutrophils 51.0%; reactive lymph-
cytes 2.0%; plasma cells 0.5%; C-
reactive protein 38 mg/L (normal <5
mg/L); bilirubin 95 µmol/L (normal
<17  µmol/L); aspartate aminotrans-
ferase 121 U/L (normal <31 U/L); ala-
nine aminotransferase 108 UL(normal
<31 U/L); and alcaline phosphatase
200 U/L (normal 35–104 U/L).
Ehrlichiosis was suspected by clinical
symptoms and leukopenia, thrombo-
cytopenia, and elevated transaminas-
es. 
Human granulocytic ehrlichiosis
(HGE) is an emerging tick-borne dis-
ease described for the first time in
1994 in the United States (1). The first
European case of HGE was reported
in Slovenia in 1996 (2). Infection with
Ehrlichia phagocytophila, the agent
of HGE, occurs in areas endemic for
Borrelia burgdorferi (3). In Estonia,
Lyme borrreliosis is frequently diag-
nosed in humans but the occurrence of
ehrlichiosis has not been established
for this region, despite our having
found some seropositive results in
Lyme borrreliosis patients (4).
This case of ehrlichiosis is the first
diagnosed in Estonia. The initial diag-
nosis was based on a typical clinical
spectrum of symptoms and clinical
laboratory findings, which are rela-
tively nonspecific, making the diag-
nosis problematic (5). Polymerase
chain reaction results for Ehrlichia
were negative, and we did not find
morula in the blood smear. Indirect
immunofluorescence assay (IFA,
MRL Diagnostics, Cypress, CA) was
used as a confirmatory serologic test.
However, results of this assay are
often negative during the initial phaseLETTERS
of the disease (5,6). On day 7 of ill-
ness, the serologic results for
immunoglobulin (Ig) M type antibod-
ies to Ehrlichia were positive (1:20)
and negative for IgG. The diagnosis of
ehrlichiosis was established, and ther-
apy with doxycycline was started.
After 4 days, the patient became
afebrile, and on day 6 she left for
home. One month later, the titers of
both types of antibodies to Ehrlichia
were increased: IgM titer was 1:160
and IgG titer was 1:128; 6 months
later, IgM antibodies were negative,
and the IgG titer remained unchanged.
Our patient had a typical spectrum
of clinical and laboratory changes to
Ehrlichia, but not very specific find-
ings of infection with E. phagocy-
tophila. The results of IFA, i.e., IgM
antibodies in the beginning of the dis-
ease and increasing titer of IgG anti-
bodies during the course of the dis-
ease, confirmed the diagnosis.
Granulocytic ehrlichiosis should be
considered in patients with tick-asso-
ciated fever.
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